Showing results (31-40 of 53) with videos related to
Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecanWalter J Loos, Jaap Verweij, Diederik F S Kehrer, et al.Cancer Chemotherapy and Pharmacology|January 22, 2008
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatmentJoan B Heijns, Maria E L van der Burg, Teun van Gelder, et al.Journal of Pharmaceutical and Biomedical Analysis|November 15, 2011
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific bindingPeter de Bruijn, Anne-Joy M de Graan, Annemieke Nieuweboer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxelAnja Henningsson, Sharon Marsh, Walter J Loos, et al.Journal of Pharmaceutical and Biomedical Analysis|July 25, 2009
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometryPeter de Bruijn, Inge M Ghobadi Moghaddam-Helmantel, Maja J A de Jonge, et al.Cancer Chemotherapy and Pharmacology|October 20, 2006
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patientsWalter J Loos, Ronald de Wit, Steven J Freedman, et al.The Oncologist|April 5, 2007
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelFrederike K Engels, Floris A de Jong, Alex Sparreboom, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicityDiederik F S Kehrer, Annelies M Bos, Jaap Verweij, et al.Cancer Chemotherapy and Pharmacology|July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.Cancer Biology & Therapy|September 18, 2007
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicityFloris A de Jong, Jessica M van der Bol, Ron H J Mathijssen, et al.Pageof 6